Antigens for cellular immunity testing
Cellular immunity (CI) plays a dominant role in host control of herpesvirus infection. Its impairment may result in the development of chronic recurrent forms of the infections with poor prognosis for the patient. Virus-specific cellular immunity examination is an important especially in the patients treated with immunosuppressive therapy (transplant recipients, oncological or autoimmune disease patients). It is beneficial also for vaccination or immunotherapy planning and efficiency monitoring.
Native antigens CMV, VZV, HSV-1, HSV-2 – CI are intended for virus-specific T- lymphocytes stimulation in tests of adoptive cellular immunity. They are dissolved in lymphocyte cultivation medium in working concentration and then lyophilized. The antigens are dissolved in sterile distilled water before the test and then patient´s leukocytes can be directly added and cultivated.
Native CMV, VZV, HSV-1 and HSV-2 antigens – conc. are native lyophilized antigens in concentrated form (0,1 mg, 0,5 mg).
Short time cultivation of virus-specific lymphocytes with the antigen results in the production of cytokines ( interferon γ, TNFα, interleukin 2 and others) that can be measured in immunoenzymatic tests, i.e. cytokine release assay (ELISA, ELISPOT) or directly in the cells after staining with monoclonal antibody (intracellular cytokine staining assay, ICS) using fluorescence activated cell sorter.
|Order no.||Product||Format||No. of tests|
|ODZ-314||Native HSV-1 antigen - CI||lyophilized||1ml|
|ODZ-315||Native HSV-2 antigen - CI||lyophilized||1ml|
|ODZ-319||Native CMV antigen – conc.||lyophilized||0,5mg|
|ODZ-320||Native VZV antigen - conc.||lyophilized||0,1mg|
|ODZ-321||Native HSV-1 antigen - conc.||lyophilized||0,1mg|
|ODZ-322||Native HSV-2 antigen - conc.||lyofilizovaný||0,1mg|
|ODZ-365||Control - CI r.t.u. (for CMV,VZV)||on request|
|ODZ-366||Control - CI r.t.u. (for HSV-1, HSV-2)||on request|
Why using Antigens for cellular immunity testing:
- Monitoring of virus-specific cellular immunity in patients with high risk of severe infection (transplanted patients, patients with immunotherapy)
- Individuals before or after vaccination against VZV
- Ready to use or concentrated antigen